knowledge -WSS

knowledge

author：focus 2025-10-01 17:19:45 - browse：2

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Telehealth startups are trying to fill the menopause care vacuum

focus

Wikipedia

WSS

There’s a way to spot data fakery. All journals should be using it

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Sudafed saga points to U.S. issues with evaluating older drugs

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Extensive review finds private equity owners jack up cost of care

Delta passengers in Vegas fall sick while waiting on flight in triple

leisure time

knowledge

explore

23andMe had bad news about my health. I wish a person had delivered it

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Trump demands the U.S. pay no more for drugs than other countries … again

Paxlovid should be available without a positive Covid test

The high cost of giving birth even with insurance

There’s a way to spot data fakery. All journals should be using it

Medicare details structure of new drug price negotiation program

Would Medicare drug price negotiations stall in a shutdown?

How to save PrEP access — and even expand it

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

hotspot

The stock market has soared this year, but will it last? Experts weigh in

There’s a way to spot data fakery. All journals should be using it

Shingles, which affected Dianne Feinstein, is on the rise

Caribou posts encouraging results on off

After a decade, new Gardasil ad campaign gets it (mostly) right

The stock market has soared this year, but will it last? Experts weigh in

focus

focus

Wikipedia

Wikipedia